Clinical Trial Update: Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated sunitinib malate in patients with advanced cervical cancer (Stage IVB, recurrent, or unresectable), including adenocarcinoma and squam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Adenosquamous Cell Carcinoma
• Cervical Cancer
• Cervical Squamous Cell Carcinoma
• Stage Ivb Cervical Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-02-16